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Summary
Background.— The mechanism underlying rapid, statin-induced event reduction in patients with
an acute coronary syndrome (ACS) remains to be clariﬁed.
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Aim.— The primary objective is to compare the efﬁcacy of rosuvastatin 20mg/day and ator-
vastatin 80mg/day in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at
three months, in ACS patients. Secondary objectives include a comparison of the effects of
early-started rosuvastatin and placebo on inﬂammatory markers.
Methods.— This is a randomized, double-blind, parallel-group study. Patients with non-ST-
segment elevation ACS, symptom onset less than 48 h before admission, and for whom a
percutaneous coronary intervention is planned, are eligible for inclusion and are randomized
into three groups (G1, G2 and G3). The study comprises two double-blind periods. Period 1 starts
at hospital admission and lasts until Day 0 (discharge or less or equal to 6 days after admission);
patients in G1 receive one tablet of rosuvastatin 20mg/day and patients in G2 and G3 receive
one matching placebo tablet per day. Period 2 starts at Day 0 and lasts for three months; patients
in G1 continue to receive rosuvastatin 20mg/day, patients in G2 receive rosuvastatin 20mg/day
and patients in G3 receive atorvastatin 80mg/day. Recruitment of 1075 patients will ensure an
80 power to detect a 3% difference in percentage change in the apoB/apoA-1 ratio and a 20%
difference in percentage change in high-sensitivity C-reactive protein.
Results.— Inclusion phase is complete; results will be reported at a later date.
Conclusion.— This is the ﬁrst trial investigating the effect of statins on apolipoproteins in ACS
patients.
© 2008 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— Le mécanisme par lequel une statine induit une réduction des évènements au cours
d’un syndrome coronaire aigu (SCA) reste à être élucidé.
Objectif.— L’objectif principal est de comparer l’efﬁcacité de la rosuvastatine 20mg/j et
de l’atorvastatine 80mg/j sur la réduction du rapport apolipoproteineB/apolipoproteine A1
(ApoB/ApoA1) à trois mois, chez des patients présentant un SCA. Les objectifs secondaires
incluent une comparaison des effets de la rosuvastatine initiée précocement versus placebo sur
les marqueurs inﬂammatoires.
Méthode.— Étude randomisée en double insu sur trois groupes parallèles. Les patients se
présentant avec un SCA sans élévation du segment ST, avec des symptômes débutant depuis
moins de 48 heures avant l’admission, et chez lesquels une angioplastie coronaire a été pro-
grammée, ont été inclus et randomisés en trois groupes (G1, G2 et G3). L’étude comprend deux
périodes en double insu, une période 1 de l’admission jusqu’à j0 (sortie de l’ hôpital ou un
maximum de six jours après l’admission), les patients du groupe G1 rec¸oivent un comprimé de
rosuvastatine 20mg/j et les patients du groupe G2 et G3 rec¸oivent un comprimé de placebo par
jour. La période 2 débute à j0 et dure jusqu’à trois mois, les patients du groupe G1 continuent
à recevoir de la rosuvastatine 20mg/j, les patients du groupe G2 rec¸oivent de la rosuvastatine
20mg/j et les patients du groupe G3 rec¸oivent de l’atorvastatine 80mg/j. Le recrutement de
1075 patients assurera une puissance de 80% pour détecter 3 % de différence sur la variation
en pourcentage de l’ApoB/ApoA1 et 20 % de différence pour l’hs- C- réactive proteine.
La phase d’inclusion est actuellement terminée, les résultats seront présentés ultérieure-
ment.
Conclusion.— Centaurus est la première étude à évaluer l’effet d’une statine sur les apolipopro-
c SC
. All
I
T
a
h
m
t
l
s
r
i
t
d
o
o
s
a
[teines chez les patients ave
© 2008 Elsevier Masson SAS
ntroduction
he updated NCEPATP III guidelines advocate the consider-
tion of intensive statin therapy for all patients admitted to
ospital with an acute coronary syndrome (ACS) —a recom-
endation that arises from the results of studies assessing
he beneﬁt of early statin treatment in this patient popu-
ation [1—5]. The mechanism underlying the early effect of
tatin therapy is still unclear, but may involve both lipid-
elated effects and other purported pleiotropic effects [6],
ncluding effects on inﬂammatory markers such as CRP and
hrombotic markers.
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The elevated plasma levels of CRP detected in the ﬁrst
ays of an ACS may reﬂect not only a high prevalence
f myocardial necrosis [7], ischaemia-reperfusion damage
r severe coronary atherosclerosis, but also an increased
ystemic inﬂammatory response, and have been associ-
ted with unfavourable short- and long-term prognoses
8—12].
The Myocardial ischemia reduction with acute choles-
erol lowering (MIRACL) study showed that the early
se of atorvastatin 80mg/day potentiated the decline in
nﬂammation in patients with ACS compared with placebo
13]. In another double-blind, placebo-controlled study in
CENTAURUS trial design
Nomenclature
ACS acute coronary syndrome
apoA-1 apolipoprotein A-1
apoB apolipoprotein B
CI conﬁdence interval
CK creatine kinase
CK-MB creatine kinase myocardial band isoenzyme
CRP C-reactive protein
hs-CRP high-sensitivity C-reactive protein
LDL-C low-density lipoprotein cholesterol
MI myocardial infarction
NCEP ATP III National cholesterol education program
adult treatment panel III
NSTE-ACS non-ST-segment elevation acute coronary
syndrome
NSTEMI non-ST-segment elevation myocardial
infarction
PCI percutaneous coronary intervention
S.D. standard deviation
STEMI ST-segment elevation myocardial infarction
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ULN upper limit of normal
90 patients admitted within 48 h of ACS onset and with
CRP concentration greater or equal to 1.4mg/dL, a rapid
decrease in CRP concentration was seen with the early
use of atorvastatin 40mg/day [14]. In both studies, CRP
concentration decreased spontaneously in the placebo
group.
Our CENTAURUS study is designed to compare the effects
of early treatment with rosuvastatin 20mg/day or atorvas-
tatin 80mg/day in patients with an ACS. Recent studies
have shown that the apoB/apoA-1 ratio may be one of the
strongest predictors of acute fatal MI [15,16]. Moreover,
apolipoprotein concentration is unaffected by fasting status,
unlike LDL-C concentration [17]. A maximal post-MI reduc-
tion in LDL-C concentration of 47% occurs at day 7 [18], and
TG concentration increases after MI by about 58% [18]. Our
study is the ﬁrst to evaluate the change in apoB/apoA-1 ratio
during the acute phase of ACS. In addition, we will investi-
gate the early effects of rosuvastatin (started before PCI)
on inﬂammatory markers.
Methods
Trial design
CENTAURUS is an international, multicentre, randomized,
double-blind, parallel-group study comparing the efﬁcacy
and safety of rosuvastatin 20mg/day versus atorvastatin
80mg/day in patients with an ACS. Patients are being
recruited from Belgium, Canada, Estonia, France, Greece,
Hungary, Ireland, Italy, Portugal, Spain and Tunisia.The study is being conducted in accordance with the Dec-
laration of Helsinki and under the principles of good clinical
practice, as laid out in the International conference on har-
monisation document ‘‘Good clinical practice: Consolidated
guidance’’ [19].
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tudy population
he inclusion criteria are:
age greater than or equal to 18 years;
diagnosed with NSTE-ACS;
admitted to hospital less than 48 h after the onset of
symptoms;
evidence of coronary artery disease in addition to
ischaemic symptoms;
a PCI planned or anticipated within four days for treat-
ment of the index event, in accordance with local or
European guidelines for PCI [20].
Patients with NSTE-ACS include those with unstable
ngina and NSTEMI [21,22].
The exclusion criteria are:
STEMI;
cholesterol-lowering medication in the preceding month;
contraindication for statin treatment;
homozygous familial hypercholesterolemia;
CK concentration greater than three times ULN and CK-MB
concentration less than two times ULN at visit 1 (if CK-MB
unavailable, cardiac troponin I or T concentration = 0 at
visit 1);
planned coronary revascularization other than primary
PCI during the current hospitalization;
coronary artery bypass graft or PCI in the three months
before visit 1;
occurrence of ventricular ﬁbrillation, sustained ventricu-
lar tachycardia, complete heart block, new onset atrial
ﬁbrillation with uncontrolled ventricular rate (greater
than 100 beats per minute), or paced ventricular rhythm
in the four weeks before visit 1;
stroke, sepsis, acute pericarditis, or any evidence of sys-
temic or pulmonary embolus in the preceding four weeks;
pregnancy;
initiation of hormone-replacement or oral contraceptive
therapy (in women) in the three months before visit 1.
andomization
he study is divided into two double-blind periods with ran-
omization at the beginning of the ﬁrst period (Fig. 1).
eriod 1 starts at the hospital admission of the patient for
n ACS and lasts until hospital discharge (or for a maxi-
um of six days). Period 2 starts at Day 0 (i.e. at hospital
ischarge or six days after admission) and lasts for three
onths.
After validation of eligibility, patients are randomized
nto one of three treatment groups (G1, G2 and G3; Fig. 1)
n a ratio of 1:2:2, by means of a telephone call to an
nteractive voice response system, as soon as possible after
nformed consent is obtained. Informed consent must be
btained before any study-related examination or drug
dministration. Participation in a pharmacogenomic sub-
tudy is optional, and requires completion of a separate
ritten consent form.ntervention
n Period 1, patients receive treatment with either one
ablet of rosuvastatin 20mg/day (G1) or one matching
402 J.-M. Lablanche et al.
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rigure 1. Study design ﬂowchart.
lacebo tablet per day (G2 and G3). The ﬁrst dose should be
aken within 48 h of symptom onset, and as soon as possible
fter randomization (ideally within 2 h of randomization).
wo doses of study medication are strongly recommended
efore the PCI. If the PCI is planned earlier, just after hos-
ital admission, the ﬁrst dose of study treatment should be
aken after randomization and the second dose as soon as
ossible after the PCI. A minimum time period of 12 h is
ecommended between the ﬁrst two doses.
After Period 1 and throughout Period 2, patients in G1
ontinue to receive rosuvastatin 20mg/day, patients in G2
c
P
d
t
slso receive rosuvastatin 20mg/day and patients in G3
eceive atorvastatin 80mg/day, in accordance with the
riginal randomization. To ensure blinding, patients are
nstructed to take one tablet and two capsules with water
nce daily, at any time of the day. Each tablet contains
osuvastatin 20mg or matching placebo and each capsule
ontains atorvastatin 40mg or matching placebo. The ﬁrst
eriod 2 dose takes place on the day after the last Period 1
ose. The ﬁnal dose is administered three months later, on
he day of visit 4. Investigators provide general diet coun-
elling to patients at the following visits.
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Assessments
Efﬁcacy assessments comprise measurement of the con-
centrations of inﬂammatory markers (hs-CRP, soluble CD40,
interleukin-10 and interleukin-18) and evaluation of the lipid
proﬁle (total cholesterol, LDL-C, high-density lipoprotein
cholesterol, TG, apoB and apoA-1).
Safety assessments include chemistry tests (creatinine,
alanine transaminase, CK and CK-MB), measurement of
the concentrations of cardiac troponin (I or T), thyroid-
stimulating hormone and haemoglobin A1c and adverse
events.
Pharmacogenomic substudy
Blood samples are taken for the central determination of
the concentrations of inﬂammatory markers and cardiac
troponin T, and for analysis of potential new markers of car-
diovascular disease.
Study outcomes
The primary efﬁcacy outcome is percentage change in the
apoB/apoA-1 ratio from Day 0 to three months. The sec-
ondary outcomes are as follows:
• percentage change in lipid concentrations from Day 0 to
one month and three months;
• percentage change in inﬂammatory marker concentra-
tions from randomization to one month and three months;
• percentage changes in lipid, cardiac troponin and inﬂam-
matory marker concentrations from randomization to
Day 0;
• percentage of patients reaching their established 2003
European LDL-C concentration target of 2.58mmol/L
(100mg/dL) [23] at three months;
• percentage of patients reaching their updated 2004
NCEP ATP III LDL-C concentration target of 70mg/dL
(1.81mmol/L) [3] at three months;
• percentage change in hs-CRP concentration from random-
ization to Day 0 (area under the curve [AUC] of hs-CRP)
and to one month and three months;
• incidence and severity of adverse events and abnormal
laboratory values during the study;
• incidence of major adverse clinical events (death, non-
fatal MI, non-fatal stroke, documented unstable angina
requiring hospitalization and repeat coronary revascular-
ization) during the study.
Sample size
Primary efﬁcacy outcome
The aim of the study is to demonstrate the superior-
ity of rosuvastatin 20mg/day over atorvastatin 80mg/day
in terms of ability to reduce the apoB/apoA-1 ratio at
three months. A 3% difference in apoB/apoA-1 reduction
is considered to be clinically meaningful [24]. To detect
such a difference between G2 and G3, assuming an S.D.
of 14%, with a two-sided test, an alpha risk of 5% and
a power of 80%, 343 evaluable patients per group are
required.
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econdary efﬁcacy outcomes
onsidering a non-inferiority margin of 3%, an S.D. of 14%
nd a 2-sided signiﬁcance level of 5%, 343 evaluable patients
er group will give 80% power to demonstrate non-inferiority
n LDL-C concentration reduction from the beginning of
eriod 2 between rosuvastatin 20mg/day (G2) and atorvas-
atin 80mg/day (G3). The upper limit of the two-sided 95%
I has to be less than 3% to conclude non-inferiority. A 3%
on-inferiority margin has been chosen as it corresponds to
ess than half of the effect of a dose doubling (statins gen-
rally produce an extra 6% reduction in LDL-C concentration
or every doubling of dose) [25].
To compare the effect of rosuvastatin 20mg/day and
lacebo on the concentration of hs-CRP and other inﬂam-
atory markers at the end of Period 1, 686 placebo-treated
atients (G2 plus G3) and 172 rosuvastatin-treated patients
G1) will give approximately 80% power to detect an abso-
ute difference of 20% in hs-CRP percentage change in
oncentration from baseline, assuming an S.D. of 70% for hs-
RP percentage change in concentration from baseline and
20% adjustment for the use of a non-parametric method
n the analysis.
Taking all these calculations into consideration, and
ssuming a 20% drop-out rate, 1075 patients will have to be
ncluded.
tatistical analysis
he statistical analysis of Period 2 data will include all
atients who have taken greater than or equal to one dose of
tudy medication, have a baseline lipid measurement at Day
and have greater than or equal to one post-baseline mea-
urement of one lipid variable. The analyses will be done
sing the last observation carried forward method.
The statistical analysis of Period 1 data will comprise sec-
ndary endpoints only and will include all patients who have
aken greater than or equal to one dose of study medication,
ave greater than or equal to one lipid variable or inﬂam-
atory marker measurement at admission and greater than
r equal to one lipid variable or inﬂammatory marker mea-
urement post-admission. Analyses will use observed data.
The safety population will consist of all randomized
atients who have taken greater than or equal to one dose
f study medication. A per-protocol population will also be
eﬁned, to provide for the occurrence of an unforeseen
vent that requires a sensitivity analysis.
Percentage change in the apoB/apoA-1 ratio from Day 0
o three months will be compared between G2 and G3 using
n analysis of variance, with treatment and country included
n the model. The hypothesis of superiority of rosuvastatin
ompared with atorvastatin will be tested by an upper limit
f 95% CI for the difference between treatments being less
han zero. Data from G1 will be summarized only.
Percentage change in LDL-C concentration from Day 0 to
ne month and three months will be compared between G2
nd G3 using the same method as for the primary efﬁcacy
utcome. Percentage change in other lipid concentrations
rom Day 0 to one month and three months will be summa-
ized.
Percentage change in hs-CRP concentration from ran-
omization to Day 0 will be compared between G1 and G2
404 J.-M. Lablanche et al.
Table 1 The effect of early, intensive statin therapy on acute coronary syndrome.
Sources Forest plot of any cardiovascular event by duration of treatment
Thompson et al. (PACT) [38]
Den Hartog et al. (PAIS) [30
Kinlay et al. (MIRACL) [13]
Liem et al. (FLORIDA) [35]
De Lemos et al. (A-Z) [29]
Arntz et al. (LCAD) [27]
Cannon et al. (PROVE-IT) [1]
Dupuis et al. (RECIFE) [31]
Serruys et al. (LIPS) [37]
Colivicchi et al. [28]
Kayikcioglu et al. (PTT) [33]
Okazaki et al. (ESTABLISH) [36]
Kesteloot et al. (LAMIL) [34]
A meta-analysis of randomised controlled trials [26] investigating the effect of early, intensive statin therapy on patients with an acute
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acoronary syndrome [32].
lus G3 using a non-parametric Wilcoxon rank sum test. Data
rom the assessments will also be described by the median
nd 10th, 25th, 75th and 90th percentiles.
The percentage change in hs-CRP concentration from Day
to one month and three months, and all the percentage
hanges in the concentrations of other inﬂammatory mark-
rs and cardiac troponin will be summarized descriptively.
he data relating to hs-CRP from randomization to Day 0 will
lso be explored using plots and AUC (assuming that more
han three measurements are available between randomiza-
ion and Day 0).
The percentage of patients reaching the 2003 Euro-
ean LDL-C concentration target [23] and updated 2004
CEPATP III LDL-C concentration target [3] will be pre-
ented, with 95% CI in each group.
nterim analysis and timelines
o interim analysis is planned. The ﬁnal version of the
rotocol was approved by the local ethics committees in
ecember 2005. The ﬁrst patient was enrolled in January
006 and by June 2007, 1120 patients had been enrolled.
iscussion
ome new data have been published since the design and
tart of the CENTARUS trial. In the A to Z trial, the hs-
RP concentrations achieved 30 days and four months after
CS were found to be associated independently with long-
erm survival [26]. In another study, atorvastatin 40mg/day
as shown to reduce CRP concentration rapidly in patients
dmitted within 48 h of onset of ACS andwith CRP concentra-
ion greater than or equal to 1.4mg/dL [14]. In CENTAURUS,
he hs-CRP concentration will be estimated at 30 days and
hree months.
More recently, a meta-analysis was published on 13
andomized controlled trials in patients with an ACS
v
c
v
c
A1,4,27—38] . Time to initiation of treatment ranged from
ne day to 14 days, with a median duration of four days.
n CENTAURUS, statin treatment will start less than or
qual to six days after hospitalization. The meta-analysis
rovides evidence that early, intensive statin therapy is
ssociated with a reduction in adverse cardiovascular out-
omes, particularly cardiovascular death, unstable angina
nd revascularization, when prescribed within 14 days of
ospitalization for ACS. These beneﬁts took more than four
onths to begin to accrue and were sustained for two
ears (Table 1). There was no signiﬁcant evidence that
eduction in LDL-C concentration inﬂuenced these results
32].
The atorvastatin for reduction of myocardial damage dur-
ng angioplasty acute coronary syndromes (ARMYDA-ACS)
tudy in patients with NSTE-ACS [39] undergoing early coro-
ary angiography (<48 h) and PCI was published after the
eta-analysis. Patients were randomized to pretreatment
ith atorvastatin (80mg, 12 h before PCI, with a further
0mg preprocedure [N = 86]) or placebo (N = 85). Patients
lready receiving statin therapy were excluded. Short-term
retreatment with atorvastatin reduced the incidence of
ardiac events compared with placebo, with the difference
eing driven essentially by a signiﬁcant reduction in peripro-
edural MI.
To date, no data have been published on the effect of
tatins on apoB or apoA-1 in patients with ACS.
onclusion
ENTAURUS will provide important information on the
nti-inﬂammatory effects of early treatment with rosu-
astatin 20mg/day, and will be the ﬁrst trial to
ompare the effects of rosuvastatin 20mg/day and ator-
astatin 80mg/day on lipid proﬁles and to explore the
hange in the apoB/apoA-1 ratio, in patients with an
CS.
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